Patrick Gladding

List of Publications by Year in Descending Order

19 papers	**371** citations	**9** h-index	**19** g-index
23 ext. papers	**484** ext. citations	**3.8** avg, IF	**2.72** L-index

#	Paper	IF	Citations
19	Multiomics, virtual reality and artificial intelligence in heart failure. *Future Cardiology*, **2021**, 17, 1335-1347	1.3	3
18	The Multi-Ethnic New Zealand Study of Acute Coronary Syndromes (MENZACS): Design and Methodology. *Neurology International*, **2021**, 11, 84-97	0	0
17	Effect of macrotroponin on the utility of cardiac troponin I as a prognostic biomarker for long term total and cardiovascular disease mortality. *Pathology*, **2021**, 53, 860-866	1.6	4
16	A machine learning PROGRAM to identify COVID-19 and other diseases from hematology data. *Future Science OA*, **2021**, 7, FSO733	2.7	0
15	Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie?. *European Heart Journal*, **2020**, 41, 1249-1257	9.5	69
14	ECG-derived spatial QRS-T angle is associated with ICD implantation, mortality and heart failure admissions in patients with LV systolic dysfunction. *PLoS ONE*, **2017**, 12, e0171069	3.7	12
13	Comparison of two-dimensional strain analysis using vendor-independent and vendor-specific software in adult and pediatric patients. *JRSM Cardiovascular Disease*, **2017**, 6, 2048004017712862	1.1	15
12	Advanced Electrocardiography Identifies Left Ventricular Systolic Dysfunction in Non-Ischemic Cardiomyopathy and Tracks Serial Change over Time. *Journal of Cardiovascular Development and Disease*, **2015**, 2, 93-107	4.2	4
11	Bioengineering silicon quantum dot theranostics using a network analysis of metabolomic and proteomic data in cardiac ischemia. *Theranostics*, **2013**, 3, 719-28	12.1	13
10	Open access integrated therapeutic and diagnostic platforms for personalized cardiovascular medicine. *Journal of Personalized Medicine*, **2013**, 3, 203-37	3.6	12
9	A simulation of warfarin maintenance dose requirement using a pharmacogenetic algorithm in an ethnically diverse cohort. *Personalized Medicine*, **2010**, 7, 319-325	2.2	4
8	Longitudinal study of a 9p21.3 SNP using a national electronic healthcare database. *Personalized Medicine*, **2010**, 7, 361-369	2.2	0
7	Clopidogrel pharmacogenomics: next steps: a clinical algorithm, gene-gene interactions, and an elusive outcomes trial. *JACC: Cardiovascular Interventions*, **2010**, 3, 995-1000	5	8
6	Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study. *JACC: Cardiovascular Interventions*, **2009**, 2, 1095-101	5	38
5	A Multi-feature Reproducibility Assessment of Mass Spectral Data in Clinical Proteomic Studies. *Clinical Proteomics*, **2009**, 5, 170-177	5	1
4	Feasibility, safety, and efficacy of a novel polymeric pimecrolimus-eluting stent: traditional pre-clinical safety end points failed to predict 6-month clinical angiographic results. *JACC: Cardiovascular Interventions*, **2009**, 2, 1017-24	5	6
3	Antiplatelet drug nonresponsiveness. *American Heart Journal*, **2008**, 155, 591-9	4.9	40

LIST OF PUBLICATIONS

2	The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial. *JACC: Cardiovascular Interventions*, **2008**, 1, 612-9	5	43
1	The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. *JACC: Cardiovascular Interventions*, **2008**, 1, 620-7	5	95